Osaic Holdings’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-18
Closed -$284 7890
2025
Q4
$284 Sell
18
-70
-80% -$889 ﹤0.01% 7532
2025
Q3
$1.05K Buy
88
+50
+132% +$400 ﹤0.01% 7332
2025
Q2
$224 Buy
38
+27
+245% +$162 ﹤0.01% 7482
2025
Q1
$61 Sell
11
-7
-39% -$43 ﹤0.01% 7271
2024
Q4
$104 Hold
18
﹤0.01% 7240
2024
Q3
$186 Sell
18
-313
-95% -$4.09K ﹤0.01% 7187
2024
Q2
$4.29K Buy
331
+35
+12% +$472 ﹤0.01% 6246
2024
Q1
$5.17K Buy
296
+285
+2,591% +$3.77K ﹤0.01% 6073
2023
Q4
$103 Hold
11
﹤0.01% 7108
2023
Q3
$123 Hold
11
﹤0.01% 7205
2023
Q2
$235 Hold
11
﹤0.01% 7177
2023
Q1
$445 Hold
11
﹤0.01% 7152
2022
Q4
$1K Hold
11
﹤0.01% 6864
2022
Q3
$1K Hold
11
﹤0.01% 6975
2022
Q2
$1K Hold
11
﹤0.01% 7065
2022
Q1
$1K Sell
11
-62
-85% -$4.03K ﹤0.01% 7025
2021
Q4
$6K Buy
73
+21
+40% +$1.65K ﹤0.01% 6532
2021
Q3
$3K Sell
52
-13
-20% -$643 ﹤0.01% 6726
2021
Q2
$3K Hold
65
﹤0.01% 6584
2021
Q1
$3K Sell
65
-1
-2% -$50 ﹤0.01% 6356
2020
Q4
$3K Sell
66
-14
-18% -$616 ﹤0.01% 5943
2020
Q3
$3K Buy
80
+46
+135% +$2.23K ﹤0.01% 5716
2020
Q2
$1K Buy
34
+32
+1,600% +$1.66K ﹤0.01% 5926
2020
Q1
$0 Buy
+2
New +$107 ﹤0.01% 6094

Other funds holding ENTA

Osaic Holdings's ENTA Position: Q1 2026 in Review

Osaic Holdings sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 18 shares — an estimated $284 sold.

Osaic Holdings first reported a position in ENTA in Q1 2020 and held it in 24 quarters. The position peaked at $6K in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Osaic Holdings reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Osaic Holdings sold 18 Enanta Pharmaceuticals shares in Q1 2026, an estimated $284.
  • Osaic Holdings first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 24 quarters.
  • Osaic Holdings's Enanta Pharmaceuticals position peaked at $6K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.